Please use this identifier to cite or link to this item: http://hdl.handle.net/20.500.12188/33869
DC FieldValueLanguage
dc.contributor.authorAleksandra Tatabitovskaen_US
dc.contributor.authorTeodora Brnjarchevska Blazevskien_US
dc.contributor.authorMarija Zdraveskaen_US
dc.contributor.authorDejan Todevskien_US
dc.contributor.authorIrfan Ismailien_US
dc.contributor.authorBojan Stoshevskien_US
dc.contributor.authorTamara Savevskaen_US
dc.contributor.authorIvan Petrovskien_US
dc.contributor.authorVladimir Joksimovicen_US
dc.contributor.authorDimitrievska, Deskaen_US
dc.contributor.authorPetlichkovski, Aleksandaren_US
dc.contributor.authorJoksimovikj, Nenaden_US
dc.date.accessioned2025-07-29T06:36:41Z-
dc.date.available2025-07-29T06:36:41Z-
dc.date.issued2024-
dc.identifier.urihttp://hdl.handle.net/20.500.12188/33869-
dc.description.abstractIntroduction. The COVID-19 pandemic has changed life across the planet, claiming approximately 7 mi- llion lives and more than 776 million cases reported globally, leaving many people with lasting sequelae. Of particular importance is understanding the immune system's defense responses against SARS-CoV-2 infection, with an emphasis on T-lymphocyte cells that modulate both cellular and humoral part. Aims. To determine epidemiological and clinical featu- res, especially comorbidities in patients who have had severe and mild COVID-19, to determine differences in cellular and humoral immune response and to co- rrelate with vaccination status for SARS CoV-2. Methods. A 6-month-prospective cohort study was conducted at the University Clinic for Pulmonology and Allergology and the Institute of Immunobiology and Human Genetics at the Faculty of Medicine - Skopje. The study included 88 patients with pre-exis- ting COVID-19 divided into two groups: patients with mild clinical manifestations and patients with severe clinical manifestations requiring hospitalization. The parameters of patients' medical history, number and type of comorbidities, parameters of cellular and hu- moral immune response, data on vaccination against SARS-CoV-2 were analyzed. Conclusion. The severity of the clinical presentation correlated directly with the number of comorbidities, and inversely with the vaccination status. Comorbidi- ties were present in 87.7% of patients with a severe clinical course. No correlation was found with the smoking status. The study showed that 97.72% of all patients had positive neutralizing antibodies for SARS- CoV-2. Positive cellular immunity had 54.55% of pa- tients, significantly higher in the group with severe COVID-19 and vaccinated patients. There was a posi- tive correlation between cellular and humoral immu- nity, but in 2 cases (4.16%) where the humoral respon- se was absent, a positive cellular response was verified.en_US
dc.language.isoenen_US
dc.publisherМакедонско лекарско друштво = Macedonian medical associationen_US
dc.relation.ispartofМакедонски Медицински Преглед = Macedonian Medical Reviewen_US
dc.subjectCOVID 19en_US
dc.subjectSARS CoV-2en_US
dc.subjectcellular and humoral immunityen_US
dc.subjectvaccinationen_US
dc.titleCELLULAR AND HUMORAL IMMUNITY IN PATIENTS WITH COVID-19 CORRELATED WITH SEVERITY OF CLINICAL PRESENTATION AND SARS COV-2 VACCINATION STATUSen_US
dc.title.alternativeЦЕЛУЛАРЕН И ХУМОРАЛЕН ИМУНИТЕТ КАЈ ПАЦИЕНТИ СО ПРЕЛЕЖАН COVID-19 ВО КОРЕЛАЦИЈА СО ТЕЖИНА НА КЛИНИЧКА СЛИКА И SARS COV-2 ВАКЦИНАЛЕН СТАТУСen_US
dc.typeArticleen_US
item.fulltextWith Fulltext-
item.grantfulltextopen-
crisitem.author.deptFaculty of Medicine-
crisitem.author.deptFaculty of Medicine-
crisitem.author.deptFaculty of Medicine-
crisitem.author.deptFaculty of Medicine-
crisitem.author.deptFaculty of Medicine-
crisitem.author.deptFaculty of Medicine-
crisitem.author.deptFaculty of Medicine-
Appears in Collections:Faculty of Medicine: Journal Articles
Files in This Item:
File SizeFormat 
MMP-2024-78-2-.pdf1.51 MBAdobe PDFView/Open
Show simple item record

Google ScholarTM

Check


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.